0001209191-20-020125.txt : 20200318
0001209191-20-020125.hdr.sgml : 20200318
20200318202058
ACCESSION NUMBER: 0001209191-20-020125
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200316
FILED AS OF DATE: 20200318
DATE AS OF CHANGE: 20200318
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pande Atul
CENTRAL INDEX KEY: 0001643071
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 20726162
MAIL ADDRESS:
STREET 1: C/O AXOVANT SCIENCES, INC.
STREET 2: 1441 BROADWAY, 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axovant Gene Therapies Ltd.
CENTRAL INDEX KEY: 0001636050
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981333697
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 11-12 ST. JAMES'S SQUARE
STREET 2: SUITE 1, 3RD FLOOR
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
BUSINESS PHONE: 44 203 318 9708
MAIL ADDRESS:
STREET 1: 11 TIMES SQUARE
STREET 2: 33RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences Ltd.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences, Inc.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Roivant Neurosciences Ltd.
DATE OF NAME CHANGE: 20150309
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-16
0
0001636050
Axovant Gene Therapies Ltd.
AXGT
0001643071
Pande Atul
C/O AXOVANT GENE THERAPIES LTD.
11 TIMES SQUARE, 33RD FLOOR
NEW YORK
NY
10036
1
0
0
0
Common Stock
2020-03-16
4
P
0
10000
1.7844
A
13370
I
By Atul C. Pande & Patricia A Pande TR DTD 08/24/2017
The reported price in Column 4 is a weighted-average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.77 to $1.82 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Includes 3,370 shares that were previously reported as directly owned.
/s/ Alison Haggerty, Attorney-in-Fact
2020-03-18